Integra LifeSciences Corporation appears in FDA premarket approval records as the applicant for two collagen-based hemostatic device families. Collastat was approved as P810006 on December 10, 1981, and Helistat as P850010 on November 8, 1985; both are class 3 devices regulated under 878.4490 and assigned the General, Plastic Surgery advisory committee designation. The supplied filings also show recent 30-day notices for manufacturing process changes at both PMAs. [3][4][1][2]
Documented product identities
The earliest supplied approvals identify Collastat (P810006, approved December 10, 1981, docket 81M-0402) and Helistat, listed as HELISTAT(TM) Absorbable Collagen Hemostatic Sponge (P850010, approved November 8, 1985, docket 85M-0557). Both carry the generic name Agent, absorbable hemostatic, collagen based, product code LMF, and device class 3. [4][3]
Later records describe the same PMAs with expanded trade names: Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Form for P810006, and Helistat Absorbable Collagen Hemostatic Agent and Helitene Absorbable Collagen Hemostatic Agent - Fibrillar Form for P850010. [1][2]
Recent supplement activity
Two 30-day notices were received August 21, 2026 and decided September 18, 2026: P810006/S115 for Collastat and P850010/S119 for Helistat and Helitene. Both are classified as Process Change - Manufacturer/Sterilizer/Packager/Supplier, and both state the activity as installation and qualification of a new Water for Injection pretreatment, generation, storage, and distribution system. Neither was flagged for expedited review. [1][2]
Filing scope and limits
The supplied collection contains four linked PMA records as of the snapshot: two original approvals and two 30-day notices, split evenly between OK30 and APPR decision codes. The smaller record sample shows the same two-and-two split. These counts describe the supplied filings only and are not measures of total portfolio, sales, or safety performance. [1][2][3][4]
The applicant name on these records is Integra LifeSciences Corporation, with filing addresses in Plainsboro, New Jersey. A separate query result lists Integra Lifesciences Corp. on P900033/S117 and Zimmer, Inc. on P060037/S099; those entries are distinct from the four records detailed here and are not treated as the same applicant identity. [1][2][7]
What the records do not establish
The filings do not document headquarters location, ownership or parent relationships, commercial availability, clinical outcomes, or customer relationships. Filing addresses appear in FDA records but are not evidence of a corporate headquarters. Any such details remain unknown from these sources. [1][3][4]





